De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

World Journal of Gastroenterology

Volumn 19, Issue 37, 2013, Pages 6278-6283

  Lian, Jiang Shan ^a   Zeng, Lin Yan ^a   Chen, Jian Yang ^a   Jia, Hong Yu ^a   Zhang, Yi Min ^a   Xiang, Dai Rong ^a   Yu, Liang ^a   Hu, Jian Hua ^a   Lu, Ying Feng ^a   Zheng, Ling ^a   Li, Lan Juan ^a   Yang, Yi Da ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Combination therapy; Decompensated liver cirrhosis; Entecavir; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B (E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATORENAL SYNDROME; HUMAN; LACTIC ACIDOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; VIRUS REPLICATION;

ADEFOVIR DIPIVOXIL; CHRONIC HEPATITIS B; COMBINATION THERAPY; DECOMPENSATED LIVER CIRRHOSIS; ENTECAVIR; LAMIVUDINE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885615825     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i37.6278     Document Type: Article

References (20)

1. Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. Clin Gastroenterol Hepatol 2009; 7: 786-792 [PMID: 19345284 DOI: 10.1016/ j.cgh.2009.03.020]
2. Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009; 93: 787-799, vii [PMID: 19577114 DOI: 10.1016/j.mcna.2009.03.002]
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/ j.jhep.2006.05.013]
4. Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 1582-1583 [PMID: 17499584 DOI: 10.1016/S0140-6736(07)60723-5]
5. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635 [PMID: 1426884]
6. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92 [PMID: 19546545 DOI: 10.1159/000218339]
7. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]
8. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
10. Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011; 2011: 918017 [PMID: 21994876 DOI: 10.4061/2011/918017]
11. Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003; 23: 89-100 [PMID: 12616454 DOI: 10.1055/s-2003-37591]
12. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698]
13. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, openlabel study. Hepatology 2011; 54: 91-100 [PMID: 21503940 DOI: 10.1002/hep.24361]
14. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL. Adefovir dipivoxil therapy for lamivudineresistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427 [PMID: 14647053 DOI: 10.1016/j.hep.2003.09.040]
15. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final longterm results. Liver Transpl 2007; 13: 349-360 [PMID: 17326221 DOI: 10.1002/lt.20981]
16. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009; 18: 1655-1666 [PMID: 19852566 DOI: 10.1517/13543780903241599]
17. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012; 35: 674-689 [PMID: 22257108 DOI: 10.1111/j.1365-2036.2011.04990.x]
18. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, De-Hertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285]
19. Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf 2011; 10: 809-818 [PMID: 21671843 DOI: 10.1517/14740338.2011.59 3507]
20. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006 [PMID: 19937695 DOI: 10.1002/hep.23346]